Article
Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma.
Lung cancer (Amsterdam, Netherlands) - 1 Feb 2014
Sun Jong-Mu, Lira Maruja, Pandya Kinnari, Choi Yoon-La, Ahn Jin Seok, Mao Mao, Han Joungho, Park Keunchil, Ahn Myung-Ju, Kim Jhingook
Abstract excerpt
OBJECTIVES: Anaplastic lymphoma kinase (ALK) rearrangement is a validated predictive marker to define patients with non-small cell lung cancer (NSCLC) who can benefit from selective ALK inhibitors. Therefore, accurate assessment of its prevalence and clinical characteristics is increasingly impor...
Topics
- Adenocarcinoma
- Anaplastic Lymphoma Kinase
- DNA Mutational Analysis
- ErbB Receptors
- Female
- Gene Rearrangement
- Humans
- Lung Neoplasms
- Male
- Middle Aged
- Mutation
- Neoplasm Recurrence, Local
- Neoplasm Staging
- Proto-Oncogene Proteins
- Proto-Oncogene Proteins p21(ras)